Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SANE-02: Sildenafil for Neonatal Encephalopathy
NCT04169191Phase 1Completed
- Sponsor
- McGill University Health Centre
- Start
- Sep 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ASP-001 in neonatal encephalopathy (NE) and birth asphyxia, sponsored by McGill University Health Centre. Primary endpoints: Death at 10 days and Hypotension at 10 days. Started Sep 2019; status: completed.
02
Drugs
ASP-001
03
Conditions
neonatal encephalopathy (NE)birth asphyxia
Beyond the preview
Go deeper on NCT04169191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04169191.